Compare HON & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HON | SNY |
|---|---|---|
| Founded | 1885 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 141.8B | 107.3B |
| IPO Year | 2011 | N/A |
| Metric | HON | SNY |
|---|---|---|
| Price | $225.90 | $46.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $252.17 | $61.50 |
| AVG Volume (30 Days) | 3.2M | ★ 3.7M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | 2.15% | ★ 3.54% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.36 | N/A |
| Revenue | ★ $36,529,000,000.00 | N/A |
| Revenue This Year | $6.79 | $3.01 |
| Revenue Next Year | $5.81 | $5.80 |
| P/E Ratio | $30.12 | ★ $6.14 |
| Revenue Growth | ★ 12.92 | N/A |
| 52 Week Low | $179.36 | $43.32 |
| 52 Week High | $248.18 | $56.00 |
| Indicator | HON | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 54.90 |
| Support Level | $214.60 | $45.20 |
| Resistance Level | $242.47 | $48.97 |
| Average True Range (ATR) | 4.90 | 0.74 |
| MACD | -2.11 | 0.23 |
| Stochastic Oscillator | 25.70 | 93.47 |
Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies, industrial automation, energy and sustainability solutions, and building automation. Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around one third of its revenue from recurring aftermarket services.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.